Clinical Trial

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-06-30
notable Trial sites expanded: 0 -> 4 locations 2026-06-30
Trial Details
NCT Number NCT07600749
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Malignant Neoplasm
Enrollment 120 participants
Start Date 2026-06-18
Primary Completion 2029-10-04 (estimated)
Study Completion 2029-10-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-03